Almac Group Celebrates 20 Years in North America with $5.2 million Expansion Creation of 79 Additional Jobs in North Carolina
September 20, 2016
Craigavon, N.I., UK, – Tuesday 20 September 2016 Almac Group, the global contract development and manufacturing organisation, is celebrating 20 years in North America by announcing a $5.2 million investment and the creation of almost 80 new jobs across its Durham, North Carolina facilities.
Almac first established presence in the US in 1996 with the opening of its clinical trial operations in Audubon, Pennsylvania. By 2000, Almac had expanded its North American presence into North Carolina through the acquisition of Applied Clinical Concepts Inc (ACCI) and Duke Clinical Research Institute Pharmacy (DCRIP) which merged to form Clinical Trial Services based in the Research Triangle Park, Durham.
“This latest investment and increase in capacity at our Durham facility is a sign of our continuing commitment to offer market driven solutions to our client base,” says Donna Christopher, Global VP Operations, Almac Clinical Services. We are delighted to mark our 20th year in the US with such a significant announcement – once again reinforcing our dedication to global expansion.”
Having experienced tremendous success in the North Carolina state over the past 16 years, it has been recognised as a significant hub for growth. Almac’s $5.2 million investment will see the expansion of its Clinical Services facility along with the development of its Diagnostics and Clinical Technologies operations based in the same area. Almac currently employs over 1,600 individuals across 6 facilities in the US, and almost 3,000 people based in Europe and Asia.
Closing in on its fifth decade of operations, Almac is firmly established as a market leader in the provision of world-class pharmaceutical contract development and manufacturing services. With further expansion in Asia and acquisitions in the UK and Ireland recently announced, Almac’s footprint is stronger than ever, positioning the organisation to better assist its global clients by providing services in their own region.
Commenting on this 20 year milestone, Robert Dunlop, President & Managing Director, Almac Clinical Services said: “Almac’s commitment to our customers remains as strong as it was when we first opened in the US twenty years ago. Our ongoing success would be impossible without the support and loyalty of our dedicated employees who remain committed to Almac’s vision. We are delighted to announce further investment in our Durham facilities enabling us to continue to support our clients’ needs and meet the increased demands for our integrated services and I look forward to our continuing success over the next twenty years and beyond.”
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has organically grown over 40 years and now employs in excess of 4,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).